首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   58552篇
  免费   17784篇
  国内免费   3174篇
  79510篇
  2024年   96篇
  2023年   512篇
  2022年   1245篇
  2021年   2255篇
  2020年   3300篇
  2019年   5120篇
  2018年   5138篇
  2017年   5009篇
  2016年   5455篇
  2015年   5973篇
  2014年   6023篇
  2013年   6504篇
  2012年   4797篇
  2011年   4183篇
  2010年   4570篇
  2009年   3233篇
  2008年   2401篇
  2007年   1738篇
  2006年   1531篇
  2005年   1357篇
  2004年   1227篇
  2003年   1159篇
  2002年   1044篇
  2001年   961篇
  2000年   777篇
  1999年   679篇
  1998年   367篇
  1997年   359篇
  1996年   314篇
  1995年   270篇
  1994年   246篇
  1993年   191篇
  1992年   245篇
  1991年   209篇
  1990年   197篇
  1989年   134篇
  1988年   119篇
  1987年   114篇
  1986年   82篇
  1985年   88篇
  1984年   48篇
  1983年   53篇
  1982年   26篇
  1981年   20篇
  1980年   16篇
  1979年   13篇
  1978年   10篇
  1969年   9篇
  1968年   8篇
  1965年   16篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
76.
MYH9-related diseases (MYH9-RD) are a group of autosomal dominant diseases caused by mutations in the MYH9 gene, which are featured by thrombocytopenia, giant platelets and granulocyte cytoplasmic inclusion bodies. MYH9-RD patients generally suffer from bleeding syndromes, progressive kidney disease, deafness, or cataracts. Here, we reported on a case of MYH9-RD. A novel heterozygous mutation of MYH9 (c.2344-2345delGTinsTA, p.T782Y) was discovered by targeted sequencing technology. Immunofluorescence analysis of neutrophils confirmed abnormal aggregation of MYH9 protein. The results of this study should expand the MYH9 gene mutation spectrum and provide reference for subsequent researchers and genetic counseling.  相似文献   
77.
Although cisplatin is one of the chemotherapeutics most frequently used in oral squamous cell carcinoma (OSCC) treatment,it exerts multiple side effects and poo...  相似文献   
78.
The molecular mechanisms underlying the involvement of oligodendrocytes in formation of the nodes of Ranvier (NORs) remain poorly understood. Here we show that oligodendrocyte-myelin glycoprotein (OMgp) aggregates specifically at NORs. Nodal location of OMgp does not occur along demyelinated axons of either Shiverer or proteolipid protein (PLP) transgenic mice. Over-expression of OMgp in OLN-93 cells facilitates process outgrowth. In transgenic mice in which expression of OMgp is down-regulated, myelin thickness declines, and lateral oligodendrocyte loops at the node-paranode junction are less compacted and even join together with the opposite loops, which leads to shortened nodal gaps. Notably, each of these structural abnormalities plus modest down-regulation of expression of Na(+) channel alpha subunit result in reduced conduction velocity in the spinal cords of the mutant mice. Thus, OMgp that is derived from glia has distinct roles in regulating nodal formation and function during CNS myelination.  相似文献   
79.
The mortality of patients with malignant gliomas remains high despite the advancement in multi-modal therapy including surgery, radio- and chemotherapy. Glioma stem cells (GSCs), sharing some characteristics with normal neural stem cells (NSCs), contribute to the cellular origin for primary gliomas and the recurrence of malignant gliomas after current conventional therapy. Accordingly, targeting GSCs proves to be a promising avenue of therapeutic intervention. The specific tropism of NSCs to GSCs provides a novel platform for targeted delivery of therapeutic agents. Tropism and mobilization of NSCs are enhanced by hypoxia through upregulating chemotactic cytokines and activating several signaling pathways. Moreover, hypoxia-inducible factors (HIFs) produced under hypoxic microenvironment of the stem cell niche play critical roles in the growth and stemness phenotypes regulation of both NSCs and GSCs. However, the definite cellular and molecular mechanisms of HIFs involvement in the process remain obscure. In this review, we focus on the pivotal roles of HIFs in migration of NSCs to GSCs and potential roles of HIFs in dictating the fates of migrated NSCs and targeted GSCs.  相似文献   
80.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号